Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice

BACKGROUND: Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue, Wu, Ben, Hossain, Md Jakir, Quagliata, Lily, O’Meara, Connor, Wilkins, Marc R., Corley, Susan, Khachigian, Levon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349441/
https://www.ncbi.nlm.nih.gov/pubmed/37452307
http://dx.doi.org/10.1186/s12967-023-04289-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349441/
https://www.ncbi.nlm.nih.gov/pubmed/37452307
http://dx.doi.org/10.1186/s12967-023-04289-y

Ejemplares similares